224 related articles for article (PubMed ID: 32827632)
21. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
22. Rucaparib: a novel PARP inhibitor for
Colombo I; Lheureux S; Oza AM
Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
[TBL] [Abstract][Full Text] [Related]
23. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Pennington KP; Walsh T; Harrell MI; Lee MK; Pennil CC; Rendi MH; Thornton A; Norquist BM; Casadei S; Nord AS; Agnew KJ; Pritchard CC; Scroggins S; Garcia RL; King MC; Swisher EM
Clin Cancer Res; 2014 Feb; 20(3):764-75. PubMed ID: 24240112
[TBL] [Abstract][Full Text] [Related]
24. Low BRCA1 and BRCA2 Germline Mutation Rates in a French-Canadian Population with a Diagnosis of Epithelial Tubo-Ovarian Carcinoma.
Bernard J; Mehros W; Gregoire J; Douville P; Renaud MC; Sebastianelli A; Langlais EL; Plante M
J Obstet Gynaecol Can; 2022 Oct; 44(10):1047-1053. PubMed ID: 35779836
[TBL] [Abstract][Full Text] [Related]
25. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
Murai J
Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
[TBL] [Abstract][Full Text] [Related]
27. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
28. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
29.
Darabi S; Braxton DR; Xiu J; Carneiro BA; Swensen J; Antonarakis ES; Liu SV; McKay RR; Spetzler D; El-Deiry WS; Demeure MJ
Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557020
[No Abstract] [Full Text] [Related]
30. Combination Treatment Strategies to Overcome PARP Inhibitor Resistance.
Soung YH; Chung J
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892162
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM
Gynecol Oncol; 2020 Feb; 156(2):377-386. PubMed ID: 31753525
[TBL] [Abstract][Full Text] [Related]
32. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
[TBL] [Abstract][Full Text] [Related]
33. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
Cho HY; Kim YB; Park WH; No JH
Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
[TBL] [Abstract][Full Text] [Related]
34. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
35. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
36. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
Lheureux S; Bruce JP; Burnier JV; Karakasis K; Shaw PA; Clarke BA; Yang SY; Quevedo R; Li T; Dowar M; Bowering V; Pugh TJ; Oza AM
J Clin Oncol; 2017 Apr; 35(11):1240-1249. PubMed ID: 28221868
[TBL] [Abstract][Full Text] [Related]
37. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
Lee JM; Ledermann JA; Kohn EC
Ann Oncol; 2014 Jan; 25(1):32-40. PubMed ID: 24225019
[TBL] [Abstract][Full Text] [Related]
38. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Kurnit KC; Coleman RL; Westin SN
Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
[TBL] [Abstract][Full Text] [Related]
39. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
[TBL] [Abstract][Full Text] [Related]
40. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
Tewari KS; Eskander RN; Monk BJ
Clin Cancer Res; 2015 Sep; 21(17):3829-35. PubMed ID: 26169965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
